Physician profile
Lijo John
NPI 1639552029
$601.95
in general payments reported to CMS, 2019-2025
11 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.14 · 2022: $24.42 · 2023: $152 · 2024: $28.91 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $383 · Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $383.12 |
| Food and Beverage | $181.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $383.12 | 2025 | |
| Orthofix Medical, INC. | $35.19 | 2023 | Physio-Stim |
| Convatec INC. | $28.91 | 2024 | |
| Depuy Synthes Sales INC. | $24.42 | 2022 | |
| Smith+Nephew, INC. | $23.94 | 2023 | Grafix Pl |
| Paratek Pharmaceuticals, INC. | $23.85 | 2023 | Nuzyra |
| Polynovo North America LLC | $21.33 | 2023 | |
| Ibsa Pharma INC. | $16.67 | 2023 | Tirosint, Licart |
| Next Science LLC | $15.75 | 2023 | Surgx, Blastx, Xperience |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2023 | Seglentis |
| Organogenesis INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lijo John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.